Recent advances in leishmaniasis treatment  by Tiuman, Tatiana S. et al.
International Journal of Infectious Diseases 15 (2011) e525–e532Review
Recent advances in leishmaniasis treatment
Tatiana S. Tiuman a,b, Adriana O. Santos b, Taˆnia Ueda-Nakamura a,b,
Benedito P. Dias Filho a,b, Celso V. Nakamura a,b,*
a Programa de Po´s-Graduac¸a˜o em Cieˆncias Farmaceˆuticas, Universidade Estadual de Maringa´, Av. Colombo 5790, 87020-900 Maringa´, Parana´, Brazil
bDepartamento de Cieˆncias Ba´sicas da Sau´de, Laborato´rio de Inovac¸a˜o Tecnolo´gica no Desenvolvimento de Fa´rmacos e Cosme´ticos, Universidade Estadual de Maringa´, Maringa´,
Parana´, Brazil
A R T I C L E I N F O
Article history:
Received 20 September 2010
Received in revised form 15 March 2011
Accepted 31 March 2011
Corresponding Editor: William Cameron,
Ottawa, Canada.
Keywords:
Leishmaniasis treatment
Drug delivery systems
Chemotherapeutics
S U M M A R Y
About 1.5 million new cases of cutaneous leishmaniasis and 500 000 new cases of visceral leishmaniasis
occur each year around the world. For over half a century, the clinical forms of the disease have been
treated almost exclusively with pentavalent antimonial compounds. In this review, we describe the
arsenal available for treating Leishmania infections, as well as recent advances from research on plants
and synthetic compounds as source drugs for treating the disease. We also review some new drug-
delivery systems for the development of novel chemotherapeutics. We observe that the pharmaceutical
industry should employ its modern technologies, which could lead to better use of plants and their
extracts, as well as to the development of synthetic and semi-synthetic compounds. New studies have
highlighted some biopharmaceutical technologies in the design of the delivery strategy, such as
nanoparticles, liposomes, cochleates, and non-speciﬁc lipid transfer proteins. These observations serve as
a basis to indicate novel routes for the development and design of effective anti-Leishmania drugs.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Leishmaniasis is an infectious disease caused by parasites of the
genus Leishmania in the family Trypanosomatidae. The disease
manifests as three types: cutaneous, mucocutaneous, and visceral
leishmaniasis, which is also known as kala-azar.1,2 Cutaneous
leishmaniasis, the most common form, is a group of diseases with a
varied spectrum of clinical manifestations, which range from small
cutaneous nodules to gross mucosal tissue destruction.3 Visceral
leishmaniasis is the most severe form, in which the parasites have
migrated to vital organs. It is a severe, debilitating disease,
characterized by prolonged fever, splenomegaly, hypergammaglo-
bulinemia, and pancytopenia. Patients gradually become ill over a
period of a few months, and nearly always die if untreated.4
Leishmaniasis is transmitted through the bite of female
phlebotomine sandﬂies infected with the protozoan. The parasite
is then internalized via macrophages in the liver, spleen, and bone
marrow.5 Leishmania parasites are dimorphic organisms, i.e., with
two morphological forms in their life cycle: amastigotes in the
mononuclear phagocytic system of the mammalian host, and
promastigotes in the digestive organs of the vector.6
About 1.5 million new cases of cutaneous leishmaniasis and
500 000 new cases of visceral disease occur each year. Cutaneous* Corresponding author. Tel.: +55 44 3011 5012; fax: +55 44 3011 5050.
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and 90% of cases occur in Afghanistan, Algeria, Brazil, Pakistan,
Peru, Saudi Arabia, and Syria.3,7,8 Visceral leishmaniasis occurs in
65 countries; the majority (90%) of cases occur in agricultural
areas and among the suburban poor of ﬁve countries: Bangladesh,
India, Nepal, Sudan, and Brazil.1,9 The number of cases is
increasing globally at an alarming rate.10 Ecological chaos caused
by humans has enabled the leishmaniases to expand beyond their
natural ecotopes, and this in turn affects the level of human
exposure to the sandﬂy vectors.11 Cases of Leishmania and human
immunodeﬁciency virus (HIV) co-infection have also recently
increased.12,13
The classical treatment of leishmaniasis requires the adminis-
tration of toxic and poorly tolerated drugs. The pentavalent
antimonials – meglumine antimoniate (Glucantime) and sodium
stibogluconate (Pentostam) – are the ﬁrst-line compounds used to
treat leishmaniasis. Other drugs that may be used include
pentamidine and amphotericin B.14,15 However, parasite resis-
tance greatly reduces the efﬁcacy of conventional medications.16 In
the last 15 years, clinical misapplication of medications has
enabled the development of generalized resistance to these agents
in Bihar, India, where half of the global visceral leishmaniasis cases
occur.7 Moreover, there are no effective vaccines to prevent
leishmaniasis.17,18
The purpose of this review is to discuss the current treatment
for leishmaniasis and to highlight recent advances in the
development of novel chemotherapies.ses. Published by Elsevier Ltd. All rights reserved.
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Pentavalent antimonials were developed in 1945, and remain
the ﬁrst-choice treatment for both visceral and cutaneous
leishmaniasis in most parts of the world. Amphotericin B and
pentamidine are the second-line antileishmanial drugs, although
they require long courses of parenteral administration.19 The
choice of treatment also depends on the causative Leishmania
species.20 The most common syndrome is localized cutaneous
leishmaniasis (CL), which is most frequently caused by Leishmania
major and Leishmania tropica in the Old World (Mediterranean
basin, Middle East, and Africa), and by Leishmania braziliensis,
Leishmania mexicana, and related species in the New World
(Mexico, Central America, and South America).21 A study of 103
patients with CL in Peru showed that among patients infected with
Leishmania (Viannia) peruviana (47.6%), Leishmania (Viannia)
guyanensis (23.3%), and Leishmania (Viannia) braziliensis (22.3%),
21 of them (21.9%) did not respond to pentavalent antimonial
chemotherapy. Therefore, accurate identiﬁcation of the parasite is
of great clinical importance, because it will guide the choice of an
appropriate treatment.20 Although spontaneous cure is the rule,
the rate of recovery varies depending on the species of Leishmania,
and may require months or years to complete healing.3
Most of the commonly used drugs are toxic and do not cure, i.e.,
eliminate the parasite, from infected individuals.19 Failure to treat
leishmaniasis successfully is often due to increased chemoresis-
tance of the parasite.15,22
Because treatment is a growing problem, the development of
new medicines that can replace or complement the presently
available therapeutic alternatives is necessary. Encouraging
advances in chemotherapy have been made in recent years.
Antileishmanial chemotherapy has improved since the develop-
ment of lipid formulations of amphotericin B, which is a much less
toxic treatment for fungal infections, and has been exploited for
the treatment of leishmaniasis.23 The unilamellar liposomal
formulation (AmBisome1), lipid complex (Abelcet1), and colloidal
dispersion (AmphocilTM) have all been evaluated in clinical trials
for visceral leishmaniasis and/or mucocutaneous leishmaniasis.
Yardley and Croft (2000) found that AmBisome and Amphocil are
more effective (50% effective dose (ED50) values 0.3 and 0.7 mg/kg,
respectively) than Abelcet (ED50 2.7 mg/kg) against Leishmania
donovani in a mouse model. AmBisome (25 mg/kg) was the most
successful in reducing the size of lesions caused by L. major, and
Amphocil (12.5 mg/kg) also showed activity, whereas Abelcet was
inactive against this species.24
However, the high cost of these amphotericin B preparations
precludes their widespread use in developing countries. New
formulations involving microcapsules made of albumin, which is a
cheap and effective carrier system and provides effective protec-
tion against phagocytic cells, have been tested. Microspheres of
hydrophilic albumin with three amphotericin B aggregation states
(monomeric, dimeric, and multiaggregate) and a multiaggregate
form encapsulated with two commercial polymers were tested
against Leishmania infantum (both extracellular promastigote and
intracellular amastigote forms). The albumin-encapsulated forms
showed no toxicity to murine cells and had lower 50% effective
concentration (EC50) values (0.003 mg/ml) for amastigotes than did
the free formulations (0.03 mg/ml). These promising results have
increased interest in amphotericin B encapsulated in micro-
spheres, and in exploring new chemotherapeutic approaches.25
Miltefosine, an alkylphospholipid, was developed as an oral
antineoplastic agent (for cutaneous cancers) and has subsequently
been applied to treat leishmaniasis.26 The discovery that milte-
fosine is effective against Leishmania led to the identiﬁcation of a
modern group of antiprotozoal medicines. Following clinical
studies, miltefosine was approved as ImpavidoTM and has becomethe ﬁrst oral treatment for leishmaniasis in some countries.27 It is
an effective treatment for visceral and cutaneous leishmaniasis,
including for antimony-resistant infections. However, this drug
may not necessarily be superior to parenteral therapies for all
forms of leishmaniasis.28 The requirement for a long treatment
period (28 days) will necessitate the formulation of strategies for
more rational use, in order to prevent patients from developing
resistance to the drug. Studies of the resistance mechanisms have
shown that possible mechanisms include a decrease in drug
uptake, differential plasma membrane permeability, more rapid
drug metabolism, and efﬂux of the drug.29 Miltefosine was
registered in India for the treatment of visceral leishmaniasis in
2002.30 It has exhibited teratogenic potential, and therefore should
not be administered to pregnant women.31
Other alkylphospholipids such as edelfosine and ilmofosine,32
as well as perifosine,33 have proved to possess potent in vitro
antiparasitic activity. In 2008, Cabrera-Serra et al. tested
edelfosine and perifosine orally in Balb/c mice infected with
Leishmania amazonensis. This pre-clinical study showed that
perifosine had higher activity in the in vivo assay and may be a
possible alternative treatment against cutaneous leishmaniasis.34
Sitamaquine is a promising oral treatment for visceral
leishmaniasis in Africa. A 28-day course of treatment was
efﬁcacious and well tolerated in 61 Kenyan patients infected by
L. donovani, with the tested dose of 2.0 mg/kg/day; however,
further studies are required to deﬁne the optimal dose. Some
adverse effects included abdominal pain, headache, and a severe
renal event. The effects of sitamaquine on the kidney need further
investigation.35
Paromomycin is the only aminoglycoside with clinically
important antileishmanial activity. Both visceral and cutaneous
forms can be treated with this antibiotic, but poor oral absorption
has led to the development of parenteral and topical formulations
for the visceral and cutaneous forms, respectively.36 In a study of
patients with a visceral form of leishmaniasis in India, Sundar et al.
(2007) found that paromomycin administered by deep gluteal
intramuscular injection (11 mg/kg/day) for 21 days was equally
effective as infusion of amphotericin B (1 mg/kg/day) for 30 days.37
In 1992 in central Tunisia, patients with cutaneous leishmaniasis
caused by L. major were treated with paromomycin ointment, but
there was no difference between the treated and control groups.38
However, new topical formulations of paromomycin have given
good results. A randomized, controlled study was undertaken to
compare the therapeutic efﬁcacy of two paromomycin topical
preparations with meglumine antimoniate. The results showed
that topical paromomycin can be a therapeutic alternative for
cutaneous leishmaniasis, although a longer period is required for
clinical healing.39 A hydrophilic gel containing 10% paromomycin
was evaluated in Balb/c mice infected with L. amazonensis and
hamsters infected with L. braziliensis. Compared to the antimony
treatment, the activity of the paromomycin gel was signiﬁcantly
higher against L. amazonensis, whereas these two medications
were equally effective against L. braziliensis. The gel formulation
may represent an alternative topical treatment for cutaneous
leishmaniasis.40
3. Plants as medicine for leishmaniasis
Plants are clearly a potential source of new antiprotozoal drugs.
The biological activity of plant extracts has been attributed to
compounds belonging to diverse chemical groups including
alkaloids, ﬂavonoids, phenylpropanoids, steroids, and terpe-
noids.41–43 To obtain a herbal medicine or an isolated active
compound, different research strategies can be employed, among
them, investigation of the traditional use, the chemical composi-
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criteria.44
In the extraction processes, different plant parts and different
solvents have generally been used. In screening for biological
activity, there is clearly substantial room for improvement in the
extraction methodologies, since a variety of techniques can be used
to prepare extracts.45,46 Usually, solvents of different polarity are
employed for the extractions. For puriﬁcation and isolation, the
active extracts of the plant are sequentially fractionated, and each
fraction and/or pure compound can be evaluated for biological
activity and toxicity. This strategy is called bioactivity-guided
fractionation, which allows tests that are simple, reproducible,
rapid, and low-cost.46,47
Promastigote, axenic amastigote, and intracellular amastigote
forms of Leishmania can be used to screen for biologically active plant
substances. Tests with standard drugs have shown that in vitro tests
on axenic amastigotes not only yield signiﬁcant results when
compared to tests on promastigotes, but they are also easy to
manipulate and quantify.47–49 This can be achieved by using a cell
counter, a colorimetric method with Alamar blue or acid
phosphatase activity, evaluating the viability of the cell population
with an MTT-based method, determining ornithine decarboxylase
activity, or using a ﬂuorescent dye such as propidium iodide and a
ﬂuorescence-activated cell sorter (FACS).47,50–52 Interestingly, the
ability to derive transgenic Leishmania-expressing reporter genes,
such as the green ﬂuorescent protein (GFP) or luciferase, has opened
up new alternatives for the development of drug-screening
tests.53,54 For screening the intracellular forms of the parasite, a
colorimetricb-lactamase assay has been used to assess the potential
of new antileishmanial drugs in the clinical isolates.55Table 1
compares some antileishmanial activities that have been reported in
the last 5 years.56–87
In vitro screenings are only the ﬁrst steps to prove the efﬁcacy
and safety of medicinal plants for application in the treatment of
leishmaniasis. In addition, variation in the efﬁcacy of drugs in
treating leishmaniasis may often result from differences in the
drug sensitivity of Leishmania species, the immune status of the
patient, or the pharmacokinetic properties of the drug.16
In reviewing the literature on the use of natural products
(plant crude extracts, fractions, isolated compounds, and
essential oils), we have become aware of the great effort by
researchers around the world to locate compounds with
antileishmanial activity. These efforts are now bearing fruit,
obtaining good results and validating natural products as
genuine sources for drug discovery.
4. Synthetic compounds as an alternative
Recent years have seen growing interest in new therapies and
the use of natural products, especially those derived from plants, as
sources of new chemotherapeutic compounds with greater activity
and fewer side effects. In view of the present unsatisfactory
situation, it is highly desirable to study new molecules obtained
from medicinal plants for leishmaniasis treatment.
Researchers worldwide continue to search for new molecules
for the treatment of leishmaniasis, and several screenings with
synthetic compounds and their derivatives have been carried out.
Brenzan et al. (2008) studied the structure–activity relationship of
coumarin () mammea A/BB isolated from the CH2Cl2 extract of
Calophyllum brasiliense leaves against promastigote and intracel-
lular amastigote forms of L. amazonensis. The derivative com-
pounds displayed signiﬁcant activity. This study demonstrated
that several aspects of the structure were important for
antileishmanial activity.88
Delﬁn et al. (2009) studied the antileishmanial activity of BTB
06237 (2-[(2,4-dichloro-5-methylphenyl)sulfanyl]-1,3-dinitro-5-(triﬂuoromethyl) benzene), a compound previously identiﬁed
through quantitative structure-activity relationship (QSAR) stud-
ies, which possesses potent and selective activity against
Leishmania parasites. In this study, several analogues of BTB
06237 were synthesized and analyzed for activity against axenic
amastigotes, their ability to reduce the level of parasitemia in
peritoneal macrophages, and their ability to generate reactive
oxygen species (ROS) in L. donovani promastigotes.89 Al-Qahtani
et al. (2009) tested the in vitro antileishmanial activity of 44
derivatives of 1,3,4-thiadiazole and related compounds against
promastigote forms of L. donovani. Micromolar concentrations of
these agents were used to study the inhibition of multiplication of
promastigotes. Seven compounds were identiﬁed as potential
antigrowth agents against the parasite.90
In addition, a series of 2,4,6-trisubstituted pyrimidines and
1,3,5-triazines were synthesized and screened for antileishmanial
activity against L. donovani. The compounds that showed the
highest in vitro activity against the parasite were screened for in
vivo activity in golden hamsters (Mesocricetus auratus) infected
with the MHOM/IN/80/Dd8 strain of L. donovani, and showed
moderate in vivo inhibition of 48–56% at a dose of 50 mg/kg  5,
intraperitoneal route for 5 days.91 Barbosa et al. (2009) evaluated
the biological activity of seven aromatic compounds prepared
through the Baylis–Hillman reaction (BHR) against the promas-
tigote form of Leishmania chagasi, and all the compounds showed
high bioactivity.92 Musonda et al. (2009) demonstrated the
synthesis and evaluation of 2-pyridyl pyrimidines with in vitro
antileishmanial activity. Moreover, they analyzed the relation
between the physicochemical properties, to demonstrate a link
between lipophilicity and antiparasitic activity. Cross-screening of
the library against cultured L. donovani parasites revealed that
compounds of this class are potent inhibitors of parasite
development in vitro.93
Poorrajab et al. (2009) carried out the synthesis and in vitro
biological evaluation of nitroimidazolyl-1,3,4-thiadiazole-based
antileishmanial agents against L. major. Most of the compounds
exhibited antileishmanial activity against the promastigote form of
L. major at non-cytotoxic concentrations. Interestingly, these
compounds were effective against intracellular L. major, and
signiﬁcantly decreased the infectivity index.94 Srinivas et al.
(2009) demonstrated the simple synthesis and potent activity of
aryloxy cyclohexyl imidazoles, a new structural class of azoles with
antileishmanial activity, both in vitro and in vivo.95 A series of 1-
phenylsubstituted b-carbolines containing an N-butylcarboxa-
mide group at C-3 of the b-carboline nucleus were synthesized and
evaluated in vitro against promastigotes of L. amazonensis. Among
all compounds tested, two derivatives showed potent activity
against the parasite. The results demonstrated that the synthesized
b-carboline-3-carboxamide derivatives have potential for use as
new drugs for the treatment of leishmaniasis.96 Aponte et al.
(2010) reported the leishmanicidal and cytotoxic activities of
tetrahydrobenzothieno-pyrimidines.97 The synthesis and in vitro
activity of R(+)-limonene derivatives against Leishmania were
described by Graebin et al. (2010). Seven compounds showed
better in vitro activity against L. braziliensis than the standard drug
pentamidine.98 Nava-Zuazo et al. (2010) synthesized a new series
of quinoline tripartite hybrids from chloroquine, ethambutol, and
isoxyl drugs, using a short synthetic route. The compounds were
tested in vitro against L. mexicana, and (4-butoxyphenyl)-N0-{2-[(7-
chloroquinolin-4-yl)amino]ethyl}urea proved to be the most
active compound against the parasites.99
These studies result from the urgent need to develop cost-
effective new drugs and to discover novel molecules with potent
antiparasitic activity and improved pharmacological characteristics.
Although many advances have been made in the treatment of
leishmaniasis, much still remains to be understood.
Table 1
Plant crude extracts, fractions, isolated compounds, and essential oils evaluated against the Leishmania genus
Family/plant species Extracts or compounds Leishmania species IC50 (mg/ml) Ref.
PRO AMA
Aloeaceae
Aloe nyeriensis Methanolic extract L. major 68.4 ND 56
Aqueous extract L. major 53.3 ND 56
Annonaceae
Annona coriacea Total alkaloids extract L. chagasi 41.6 ND 57
Annona crassiﬂora Total alkaloids extract L. chagasi 24.9 ND 57
Annona muricata Ethyl acetate extract L. amazonensis 25.0 NT 58
Guatteria australis Total alkaloids extract L. chagasi 37.9 ND 57
Polyalthia suaveolens Methanolic extract L. infantum 1.8 8.6 59
Pseudomalmea boyacana Ethyl acetate extract L. amazonensis 48.9 NT 58
Rollinia exsucca Hexane extract L. amazonensis 20.8 NT 58
Rollinia pittieri Hexane extract L. amazonensis 12.6 NT 58
Xylopia aromatica Methanolic extract L. amazonensis 20.8 NT 58
Apocynaceae
Himatanthus sucuuba Ethanolic extract L. amazonensis 20.0 5.0 60
Pagiantha cerifera Dichloromethane extract L. amazonensis 25.0 12.5 61
Asteraceae
Achillea millefolium Essential oil L. amazonensis 7.8 6.5 62
Anthemis auriculata Anthecotulide L. donovani NT 8.18 63
4-Hydroxyanthecotulide L. donovani NT 3.27 63
4-Acetoxyanthecotulide L. donovani NT 12.5 63
Baccharis dracunculifolia Crude extract L. donovani 45.0 NT 64
Hautriwaic acid lactone L. donovani 7.0 NT 64
Ursolic acid L. donovani 3.7 NT 64
Uvaol L. donovani 15.0 NT 64
2a-Hydroxy-ursolic acid L. donovani 19.9 NT 64
Calea montana Ethanolic extract L. amazonensis NT 10.0 65
Elephantopus mollis Dichloromethane extract L. donovani NT 0.6 66
Tanacetum parthenium Plant powder L. amazonensis 490 74.8 67
Dichloromethane extract L. amazonensis 3.6 2.7 67
Parthenolide L. amazonensis 0.37 0.81 68
Guaianolide L. amazonensis 2.6 ND 69
Vernonia polyanthes Methanolic extract L. amazonensis 4.0 NT 70
Caricaceae
Carica papaya Ethanolic extract L. amazonensis NT 11.0 65
Celastraceae
Maytenus putterlickoides Methanolic extract L. major 60.0 ND 56
Clusiaceae
Calophyllum brasiliense () Mammea A/BB L. amazonensis 3.0 0.88 71
Crassulaceae
Kalanchoe pinnata Quercetin diglycoside L. amazonensis NT 45.0 72
Fabaceae
Acacia tortilis Aqueous extract L. major 52.9 ND 56
Albizia coriaria Aqueous extract L. major 66.7 ND 56
Copaifera reticulata Oleoresin L. amazonensis 5.0 15.0 73
Flacourtiaceae
Laetia procera Casearlucine A L. amazonensis 11.1 5.98 74
Caseamembrol A L. amazonensis 11.0 10.5 74
Laetiaprocerine A L. amazonensis 10.9 47.4 74
Laetiaprocerine D L. amazonensis 50.9 30.3 74
Butanolide L. amazonensis 111.0 129.0 74
Ginkgoaceae
Ginkgo biloba Isoginkgetin L. amazonensis NT 1.9 75
Goodeniaceae
Scaevola balansae Dichloromethane extract L. amazonensis 8.7 NT 76
Lamiaceae
Hyptis lacustris Ethanolic extract L. amazonensis NT 10.0 65
Ocimum gratissimum Essential oil L. amazonensis 135.0 100.0 77
Eugenol L. amazonensis 80.0 NT 77
Methanolic extract L. chagasi 71.0 NT 70
Premna serratifolia Dichloromethane extract L. amazonensis 4.4 NT 76
Lecythidaceae
Careya arborea Arborenin L. donovani 15.0 12.5 78
Liliaceae
Asparagus racemosus Methanolic extract L. major 58.8 ND 56
Aqueous extract L. major 56.8 ND 56
Malpighiaceae
Lophanthera lactescens LLD3 L. amazonensis NT 0.41 79
Meliaceae
Dysoxylum binectariferum Chloroform fraction L. donovani 50.0 ND 80
Rohitukine L. donovani 100.0 ND 80
Menispermaceae
Cissampelos ovalifolia Total alkaloids extract L. chagasi 63.9 ND 57
Olacaceae
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Table 1 (Continued )
Family/plant species Extracts or compounds Leishmania species IC50 (mg/ml) Ref.
PRO AMA
Minquartia guianensis Dichloromethane extract L. donovani NT 2.8 66
Papaveraceae
Bocconia integrifolia n-Hexane extract L. donovani NT 1.8 66
Dichloromethane extract L. donovani NT 0.5 66
Methanol extract L. donovani NT 0.7 66
Piperaceae
Piper auritum Essential oil L. donovani 12.8 22.3 81
Piper dennisii Ethanolic extract L. amazonensis NT 10.0 65
Piper hispidum Ethanolic extract L. amazonensis 69.0 5.0 82
Piper regnellii Eupomatenoid-5 L. amazonensis 9.0 5.0 83
Piper strigosum Ethanolic extract L. amazonensis >100 7.8 82
Piper sp Dichloromethane extract L. donovani NT 2.2 66
Poaceae
Cymbopogon citratus Essential oil L. amazonensis 1.7 3.2 84
Citral L. amazonensis 8.0 25 84
Rhamnaceae
Gouania lupuloides Dichloromethane extract L. donovani NT 1.9 66
Methanol extract L. donovani NT 2.9 66
Rutaceae
Galipea panamensis Coumarin compound 1 L. panamensis NT 9.9 85
Coumarin compound 2 L. panamensis NT 10.5 85
Phebalosin L. panamensis NT 14.1 85
Artifact murralongin L. panamensis NT >100 85
Murrangatin acetonide L. panamensis NT NT 85
Scrophulariaceae
Scoparia dulcis Dichloromethane extract L. donovani NT 1.8 66
Scrophularia cryptophila Crypthophilic acid A L. donovani NT 12.8 86
Crypthophilic acid C L. donovani NT 5.8 86
Harpagide L. donovani NT 2.0 86
Acetylharpagide L. donovani NT 6.9 86
Buddlejasaponin III L. donovani NT 6.2 86
Solanaceae
Brugmansia sp Dichloromethane extract L. donovani NT 3.0 66
Umbelliferae
Ferula szowitsiana Auraptene L. major 5.1 NT 87
Umbelliprenin L. major 4.9 NT 87
Verbenaceae
Lantana sp Ethanolic extract L. amazonensis NT 10.0 65
Zingiberaceae
Hedychium coronarium Ethanolic extract L. amazonensis NT 10.0 65
PRO, promastigote; AMA, amastigote; IC50, concentration in mg/ml that inhibits growth of 50% of the cells; NT, not tested; ND, not determined.
T.S. Tiuman et al. / International Journal of Infectious Diseases 15 (2011) e525–e532 e5295. What is the future of antileishmanial agents?
Leishmaniasis represents a signiﬁcant global burden and a great
challenge to drug discovery and delivery, because of the
intracellular nature and disseminated locations of the parasite.
The potential of some colloidal drug carriers such as emulsions,
liposomes, and nanoparticles is of great interest, mainly due to
their versatile nature and attractive advantages in the context of
parasitic diseases.
The potential of medicine delivery systems based on the
controlled release of drugs, especially nanoparticles (NPs), is
attracting increased attention. NPs are submicron moieties
(between 1 nm and 100 nm) and are considered ‘intelligent’
particles with a magnetic core, a recognition layer, and a
therapeutic load. They are made of inorganic or organic materials,
which may or may not be biodegradable.100
Biodegradable nanoparticles (such as PLGA, PLA, chitosan,
gelatin, polycaprolactone, and polyalkylcyanoacrylates) are fre-
quently used as drug delivery vehicles because of their therapeutic
value in reducing the risks of toxicity of some medicinal drugs.
They can increase the bioavailability, solubility, and retention time
of many potent drugs that are difﬁcult to deliver orally.101
Scientists who work with modern technologies for oral
formulations must overcome the hurdle of poor aqueous solubility
of many drugs. Many reports have demonstrated the advantages of
nanoformulations for improving oral bioavailability in vivo.
Nanosizing will attract increased attention as an option forformulations affording immediate release for oral administra-
tion.102
Nanoparticles can be useful in treating some macrophage-
mediated diseases. Mononuclear phagocyte cells engulf Leishmania
parasites, but also remove drug particles from the body circulation.
The characteristic of macrophages to recognize cell-surface ligands
is exploited in nanoparticulate systems, by anchoring speciﬁc
entities to ensure their internalization into the cells.103
Liposomes and nanoparticles have shown great potential for
improving the efﬁcacy and tolerability of antileishmanial drugs
such as liposomal amphotericin B. Solid lipid nanoparticles and
nanostructured lipid carriers represent a second generation of
colloidal carriers, mainly because of their better stability and ease
of commercialization.104
Amphotericin B has poor solubility, and because it is not
absorbed in the gastrointestinal tract, it must be administered by
slow intravenous injection. An oral delivery system is desirable,
and modern studies aimed at increasing oral absorption have
evaluated nanosuspensions.105 Amphotericin B formulated in a
nanosuspension for oral delivery was tested against L. donovani
infection in a Balb/c mouse model. The amphotericin B nanosus-
pensions signiﬁcantly reduced parasite numbers in the liver.106
Cochleates, a novel lipid particle-based delivery system, also
have potential for oral administration of hydrophobic drugs such
as amphotericin B. The cochleate system promotes the uptake of
amphotericin B from the gastrointestinal tract, and has been
shown to be effective in a mouse model of systemic candidiasis.
T.S. Tiuman et al. / International Journal of Infectious Diseases 15 (2011) e525–e532e530This route of administration may have potential for therapeutic
application.107
Mendoza et al. (2008) proposed a novel formulation for
edelfosine by developing a lipid nanoparticulate system, with the
purpose of decreasing systemic toxicity and improving the
therapeutic potential of the drug. The lipid employed Compritol1,
which presents advantages in vitro as a matrix material for
nanoparticle development and the controlled release of edelfo-
sine.108
Non-speciﬁc lipid transfer proteins (nsLTPs) from plants are
small basic proteins, and can be subdivided into nsLTP1 (10 kDa)
and nsLTP2 (7 kDa) according to their molecular weight.109 These
proteins can bind a broad range of lipid molecules, and have
attracted increasing interest as potential drug carriers. nsLTPs have
been puriﬁed from a variety of plants including barley seeds and
hops,110 rice,111 tomato,112 the pandan Pandanus amaryllifolius,113
and cumin Cuminum cyminum.114
These carriers have a transfer activity that should make them
useful when drugs must cross through the lipid membranes. The
study of complex formation between nsLTP1 and several drugs is
likely to allow additional pharmaceutical applications. A study by
Pato et al. (2001) demonstrated that wheat nsLTP1 can bind ether
phospholipid analogues (edelfosine, ilmofosine) and an antifungal
conazole derivative (BD56) with similar afﬁnity. Pato and co-
workers also showed an interaction between amphotericin B and
nsLTP1, although they could demonstrate no afﬁnity. Their study
suggests a potential application of nsLTPs as antileishmanial drug
carrier systems.115
Combination chemotherapy has improved prospects for curb-
ing the emergence of drug resistance, and has proven to increase
activity through the use of compounds with synergistic or additive
activity, reducing required doses and toxic side effects.16 In a
recent study, WR279,396, a topical formulation containing 15%
paromomycin and 0.5% gentamicin was evaluated in a phase II trial
in Tunisia and France. The treatment for 20 days was safe and
effective against CL caused by L. major.116
The effectiveness of drug combinations in chemotherapy is
measured by the interaction index. This methodology uses
combination and individual drug dose–effect data and employs
isobolar analysis, and fractional inhibitory concentrations (FIC) can
be calculated.117 Monzote et al. (2007) showed that the essential
oil from Chenopodium ambrosioides had a synergic effect with
pentamidine against promastigotes of L. amazonensis, but found an
indifferent effect for combinations with meglumine antimoniate or
amphotericin B.118 The current trend is to investigate the
possibility of increasing the effects of antibiotics or synthetic
drugs by combining them with natural products such as plants
used in traditional medicine. Some new projects aim to develop a
new generation of phytochemicals, which can be used alone or in
combination with antibiotics or synthetic drugs. These new
formulations of combinations of medicine could be used to cure
diseases that are presently treated using synthetic drugs alone.119
6. Conclusions
Pharmaceutical research on natural products represents a
major strategy for discovering and developing new drugs. There
are many possibilities for research, but priority should be given to
tropical infectious and chronic diseases for which current
medications have severe drawbacks, and to the scientiﬁc appraisal
of plant-based remedies that might be safer, cheaper, and less toxic
than existing prescription medicines. This is an area rich in
possibilities, and the world’s ﬂora represents an enormous source
of material for testing. What is needed now is funding to support
this type of research.Industry should play a role, because of its greater knowledge of
modern technologies, which may lead to better utilization of plants
and their extracts, and their funding and marketing. Development
of new molecules to treat leishmaniasis is necessary. The
development of drug combinations and new pharmaceutical
technologies is still an open area for research. The biological and
biopharmaceutical issues should be considered in the design of
delivery strategies for treating parasitic infections such as
leishmaniasis.
Conﬂict of interest: No conﬂict of interest to declare.
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